Teva Pharmaceutical Industries Limited’s Edratide for Systemic Lupus Erythematosus Did Not Meet Its Primary Endpoint in Phase 2 Trial

JERUSALEM--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) announced today that the Company’s synthetic peptide, edratide (TV-4710), did not meet its primary endpoint in the PRELUDE trial, a Phase 2 clinical trial in patients with systemic lupus erythematosus (SLE). The drug candidate, administered as a subcutaneous weekly injection, was shown to be safe and well-tolerated. PRELUDE, a randomized, double-blind, placebo-controlled, parallel assignment Phase 2 study, enrolled 340 patients from 12 countries across North America, Latin America, the European Union, Russia, and Israel. The study was designed to assess the efficacy and safety of edratide, with the primary endpoint being the reduction of lupus disease activity over a 26-week treatment period, as measured by the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) score.

MORE ON THIS TOPIC